40
Participants
Start Date
March 1, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
March 1, 2026
Toripalimab
"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."
RECRUITING
the second affiliated hospital of Army medical university, Chongqing
RECRUITING
Xinqiao Hospital of Chongqing, Chongqing
Southwest Hospital, China
OTHER
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER
Chongqing University Cancer Hospital
OTHER
Xinqiao Hospital of Chongqing
OTHER